

RESEARCH LETTER

# Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL

Nicholas A. Marston, MD, MPH; Robert P. Giugliano, MD, SM; Jeong-Gun Park, PhD; Andrea Ruzza<sup>1</sup>, MD, PhD; Peter S. Sever, MB BChir, PhD; Anthony C. Keech, MD; Marc S. Sabatine, MD, MPH

The American College of Cardiology/American Heart Association/Multisociety cholesterol guidelines recommend adding a nonstatin if the low-density lipoprotein cholesterol (LDL-C) remains  $\geq 70$  mg/dL in patients with high-risk atherosclerotic cardiovascular disease ASCVD,<sup>1</sup> effectively creating a target of  $< 70$  mg/dL. The 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines go further and recommend an LDL-C goal of  $< 55$  mg/dL for patients with very high-risk ASCVD and to consider an even lower goal of  $< 40$  mg/dL for patients with multiple cardiovascular events within 2 years despite optimal statin therapy.<sup>2</sup> The advent of PCSK9 inhibition allows many patients to achieve even lower LDL-C levels. For example, evolocumab lowered LDL-C by 59% when added to statin therapy in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), reducing LDL-C from a median of 93 mg/dL to 30 mg/dL.<sup>3</sup> Nevertheless, a key question is whether there is evidence of continued clinical benefit with lowering LDL-C below 40 mg/dL.

An analysis from FOURIER showed no significant heterogeneity in clinical benefit of evolocumab between patients with a baseline LDL-C less than versus greater than or equal to 70 mg/dL, but this analysis did not address the fraction of LDL-C lowering below subsequently published targets.<sup>4</sup> Another analysis demonstrated a strong relationship between achieved LDL-C at 1 month and adjusted risk of cardiovascular events.<sup>5</sup> However, this was a postrandomization association analysis, which carries the risk of confounding. Therefore, in the current analysis, we aimed to determine whether there is continued cardiovascular benefit from lowering LDL-C to  $< 40$  mg/dL

using comparisons of randomized groups and analyzing in the context of the magnitude of LDL-C lowering below the most recent recommended targets.

To achieve this aim, we performed an exploratory analysis in FOURIER, a cardiovascular outcomes trial comparing evolocumab with placebo in patients with stable ASCVD on optimized statin therapy.<sup>3</sup> Major adverse cardiovascular events were defined as cardiovascular death, myocardial infarction, or stroke. Median follow-up was 2.2 years. We used a Cox proportional hazard regression model to determine the hazard ratio for major adverse cardiovascular events for evolocumab versus placebo (normalized per 39 mg/dL [1 mmol/L] reduction in LDL-C) across the range of baseline LDL-C. When LDL-C was  $< 40$  mg/dL, ultracentrifugation was performed. Nonetheless, we also performed analogous analyses using apolipoprotein B and non-high-density lipoprotein cholesterol given they are metrics of all atherogenic lipoproteins and there are no analytic concerns. Each site's ethics committee approved the trial protocol, and all subjects provided informed consent. Data will not be made publicly available; however, interested parties can contact the corresponding authors.

Among 27 564 patients with ASCVD enrolled in FOURIER (mean age, 63 years; 75% men), 81% had previous myocardial infarction, 19% previous ischemic stroke, and 13% peripheral artery disease. A total of 80% had hypertension, 37% had diabetes, and 28% were smokers. The median baseline LDL-C was 93 mg/dL (interquartile range, 80–109 mg/dL) with 99% on a moderate- or high-intensity statin regimen. Of subjects randomized to evolocumab, 65% achieved an LDL-C  $< 40$  mg/dL.

In the Figure (A), top, the achieved LDL-C (y axis) is plotted as a function of baseline LDL-C (x-axis) in each

**Key Words:** cholesterol ■ coronary artery disease ■ lipids ■ lipoproteins, LDL ■ therapeutics


Correspondence to: Nicholas A. Marston, MD, MPH, 60 Fenwood Rd, Boston, MA 02115. Email nmarston@bwh.harvard.edu

This work was presented as an abstract at the European Society of Cardiology Congress, August 27–30, 2021.

For Sources of Funding and Disclosures, see page 1733.

© 2021 American Heart Association, Inc.

Circulation is available at [www.ahajournals.org/journal/circ](http://www.ahajournals.org/journal/circ)



### Figure. Cardiovascular benefit of continued LDL-C lowering below 40 mg/dL and equivalent thresholds of apoB and non-HDL-C.

**A, Top**, Achieved low-density lipoprotein cholesterol (LDL-C) at 48 weeks as a function of baseline LDL-C. The shaded area represents the amount of LDL-C lowering that occurred between the treatment arms at a given baseline LDL-C, with blue shading representing LDL-C lowering that occurred above 40 mg/dL and red shading representing LDL-C lowering that occurred below 40 mg/dL. The further baseline LDL-C levels were below 93 mg/dL (black dashed line), the greater the proportion of LDL-C lowering that was below 40 mg/dL, ranging from, on average, 0% at 93 mg/dL to 38% at 58 mg/dL. **Bottom**, Hazard ratio for evolocumab (Evo) versus placebo for cardiovascular death, myocardial infarction (MI), or stroke per 39 mg/dL (1 mmol/L) reduction in LDL-C as a function of baseline LDL-C. As the proportion of LDL-C lowering below 40 mg/dL increased, there was no evidence of attenuation in treatment effect ( $P$  value for treatment interaction = 0.78). **B**, Hazard ratio for evolocumab versus placebo for cardiovascular death, MI, or stroke per 39 mg/dL (1 mmol/L) reduction in LDL-C as a function of baseline apolipoprotein B (apoB). The further baseline apoB levels were below 98 mg/dL (black dashed line), the greater the proportion of apoB lowering that was below 50 mg/dL. As the proportion of apoB lowering below 50 mg/dL increased, there was no evidence of attenuation in treatment effect ( $P$  value for treatment interaction = 0.62). **C**, Hazard ratio for evolocumab versus placebo for cardiovascular death, MI, or stroke per 39 mg/dL (1 mmol/L) reduction in LDL-C as a function of baseline non-high-density lipoprotein (non-HDL-C). The further baseline non-HDL-C levels were below 147 mg/dL (black dashed line), the greater the proportion of non-HDL-C that was below 70 mg/dL. As the proportion of non-HDL-C lowering below 70 mg/dL increased, there was no evidence of attenuation in treatment effect ( $P$  value for treatment interaction = 0.60). MACE indicates major adverse cardiovascular event.

treatment arm. The shaded area represents the amount of LDL-C lowering that occurred between the treatment arms at a given baseline LDL-C, with blue shading representing LDL-C lowering that occurred above 40 mg/dL and red shading representing LDL-C lowering that occurred below 40 mg/dL. As the baseline LDL-C level went below 93 mg/dL, the mean achieved LDL-C went below 40 mg/dL. Thus, the further baseline LDL-C levels were below 93

mg/dL, the greater the proportion of LDL-C lowering was below 40 mg/dL, ranging from, on average, 0% of the difference between treatment arms at 93 mg/dL, to 38% of the difference between treatment arms when the starting LDL-C was 58 mg/dL.

If there were no benefit of lowering LDL-C below 40 mg/dL, then one would expect the hazard ratio to be progressively attenuated (ie, increase toward 1.0)

the lower the baseline LDL-C was below 93 mg/dL (ie, toward the left side of the hazard ratio curve, Figure [A], bottom) because a progressively greater proportion of the LDL-C lowering with evolocumab would be below 40 mg/dL. However, in contrast, we observed a consistent benefit of LDL-C lowering regardless of how low the baseline LDL-C was. Specifically, despite more than one-third of LDL-C lowering occurring below 40 mg/dL in subjects with baseline LDL-C of 58 mg/dL, the clinical benefit of LDL-C lowering was not attenuated ( $P$  interaction=0.78), with robust reductions in the risk of major adverse cardiovascular events (Figure [A]). A similar pattern was seen for apolipoprotein B and non-high-density lipoprotein lowering (Figure [B and C]). There was also no attenuation in the absolute risk reduction at lower baseline LDL-C ( $-2.1\%$  when baseline LDL-C was 70 to  $<90$  mg/dL and  $-1.9\%$  when it was 90–110 mg/dL).

Over the last 2 decades, we have seen the guidelines shift to lower and lower LDL-C goals on the basis of clinical trials demonstrating that lower is better. The European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines have selected an LDL-C goal of  $<40$  mg/dL as the next step in this progression. Previous clinical trials have proven that such levels are safe,<sup>3</sup> and we have demonstrated in this study that there is continued effectiveness even below 40 mg/dL in patients with high-risk ASCVD.

In conclusion, these data support the European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines recommendations and suggest that lowering LDL-C well below 40 mg/dL in a wider range of patients with ASCVD would further lower cardiovascular risk.

## ARTICLE INFORMATION

### Affiliations

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., R.P.G., J.-G.P., M.S.S.). Amgen, Thousand Oaks, CA (A.R.). National Heart and Lung Institute, Imperial College London, United Kingdom (P.S.S.). Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia (A.C.K.).

### Acknowledgments

N.A.M. contributed to study design, literature search, statistical analysis, data interpretation, figures, and drafting of the article. R.P.G. and M.S.S. contributed to study design, statistical analysis, data interpretation, figures, and critical review of the article. J.-G.P. contributed to data preparation, study design, and statistical analysis. A.R., P.S.S., and A.C.K. contributed to data interpretation and critical review of the article. M.S.S. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

### Sources of Funding

The FOURIER trial was sponsored by Amgen.

## Disclosures

Dr Marston reports grant support from the National Institutes of Health and involvement in clinical trials with Amgen, Ionis, Pfizer, Novartis, and AstraZeneca without personal fees, payments, or increase in salary. Dr Guigliano reports grants from Amgen and Daiichi Sankyo during the conduct of the study; personal fees from Akcea, grants and personal fees from Amgen, personal fees from the American College of Cardiology, grants and personal fees from Amgen, personal fees from Bristol Myers Squibb, personal fees from CVS Caremark, grants and personal fees from Daiichi Sankyo, personal fees from GlaxoSmithKline, personal fees from Janssen, personal fees from Lexicon, grants and personal fees from Merck, personal fees from Pfizer, and personal fees from Servier, outside the submitted work; and an institutional research grant to the TIMI Study Group at Brigham and Women's Hospital for research he is not directly involved in from Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc, BRAHMS, Daiichi Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, and Zora Biosciences. Dr Park is a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women's Hospital from Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Daiichi-Sankyo, Eisai, Intarcia, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc, Roche, The Medicines Company, and Zora Biosciences. Dr Ruzza is an Amgen employee and stockholder. Dr Sever reports research grants and honoraria for the speakers bureau from Amgen and Pfizer. Dr Keech reports grants and personal fees from Abbott, personal fees from Amgen, personal fees from AstraZeneca, grants and personal fees from Mylan, personal fees from Pfizer, grants from Sanofi, grants from Novartis, and personal fees from Bayer, outside the submitted work. Dr Sabatine reports research grant support through Brigham and Women's Hospital from Amgen, AstraZeneca, Bayer, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, IONIS, Janssen Research and Development, The Medicines Company, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, and Takeda; and consulting for Amgen, Anthos Therapeutics, AstraZeneca, Bristol-Myers Squibb, CVS Caremark, DalCor, Dyrnamix, Esperion, Fibrogen, IFM Therapeutics, Intarcia, Ionis, Janssen Research and Development, The Medicines Company, MedImmune, Merck, Novartis, and Novo Nordisk. He is a member of the TIMI Study Group, which has also received institutional research grant support through Brigham and Women's Hospital from Abbott, Aralez, Roche, and Zora Biosciences.

## REFERENCES

1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. doi: 10.1016/j.jacc.2018.11.002
2. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41:1111–1188. doi: 10.1093/eurheartj/ehz455
3. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722. doi: 10.1056/NEJMoa1615664
4. Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, Ferreira J, Pineda AL, Somaratne R, Sever PS, et al. Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial. *JAMA Cardiol*. 2017;2:1385–1391. doi: 10.1001/jamacardio.2017.3944
5. Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, et al; FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. *Lancet*. 2017;390:1962–1971. doi: 10.1016/S0140-6736(17)32290-0